MA56535A - Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents
Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associéesInfo
- Publication number
- MA56535A MA56535A MA056535A MA56535A MA56535A MA 56535 A MA56535 A MA 56535A MA 056535 A MA056535 A MA 056535A MA 56535 A MA56535 A MA 56535A MA 56535 A MA56535 A MA 56535A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- vaccines
- hepatitis
- virus
- self
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863961P | 2019-06-20 | 2019-06-20 | |
| US202063006925P | 2020-04-08 | 2020-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56535A true MA56535A (fr) | 2022-04-27 |
Family
ID=71833364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056535A MA56535A (fr) | 2019-06-20 | 2020-06-19 | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220313815A1 (fr) |
| EP (1) | EP3986458A1 (fr) |
| AU (1) | AU2020298267A1 (fr) |
| CA (1) | CA3143632A1 (fr) |
| MA (1) | MA56535A (fr) |
| TW (2) | TWI769467B (fr) |
| WO (1) | WO2020255055A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| WO2022150773A2 (fr) * | 2021-01-11 | 2022-07-14 | The Regents Of The University Of California | Constructions d'arn activées par un ribozyme et leurs utilisations |
| EP4376883A4 (fr) * | 2021-07-30 | 2025-07-16 | Arcturus Therapeutics Inc | Vaccins à arn |
| CN115960922A (zh) * | 2021-10-09 | 2023-04-14 | 吴可行 | 自复制rna分子设计及其应用 |
| US12115217B2 (en) | 2022-11-18 | 2024-10-15 | Trustees Of Boston University | Self-replicating RNA and uses thereof |
| WO2025040709A1 (fr) * | 2023-08-24 | 2025-02-27 | BioNTech SE | Systèmes et compositions comprenant des réplicases à amplification trans hautement actives |
| WO2025088152A1 (fr) | 2023-10-27 | 2025-05-01 | Ziphius Nv | 5'utr modifiées |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| NZ747635A (en) | 2016-03-28 | 2024-05-31 | Ichor Medical Systems Inc | Method and apparatus for delivery of therapeutic agents |
| ES2993107T3 (en) | 2016-10-17 | 2024-12-23 | Janssen Pharmaceuticals Inc | Recombinant virus replicon systems and uses thereof |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| MA51311A (fr) * | 2017-12-19 | 2020-10-28 | Janssen Sciences Ireland Unlimited Co | Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
| CA3085492A1 (fr) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methodes et appareil pour l'administration de vaccins contre le virus de l'hepatite b (vhb) |
| JP2021506300A (ja) * | 2017-12-19 | 2021-02-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物 |
| EP3864027A1 (fr) * | 2018-10-08 | 2021-08-18 | Janssen Pharmaceuticals, Inc. | Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques |
-
2020
- 2020-06-19 EP EP20746697.0A patent/EP3986458A1/fr active Pending
- 2020-06-19 CA CA3143632A patent/CA3143632A1/fr active Pending
- 2020-06-19 MA MA056535A patent/MA56535A/fr unknown
- 2020-06-19 US US17/596,874 patent/US20220313815A1/en not_active Abandoned
- 2020-06-19 AU AU2020298267A patent/AU2020298267A1/en not_active Abandoned
- 2020-06-19 WO PCT/IB2020/055775 patent/WO2020255055A1/fr not_active Ceased
- 2020-06-19 TW TW109120795A patent/TWI769467B/zh not_active IP Right Cessation
- 2020-06-19 TW TW111120040A patent/TWI828168B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020298267A1 (en) | 2022-02-17 |
| CA3143632A1 (fr) | 2020-12-24 |
| TWI769467B (zh) | 2022-07-01 |
| TW202108598A (zh) | 2021-03-01 |
| US20220313815A1 (en) | 2022-10-06 |
| WO2020255055A1 (fr) | 2020-12-24 |
| EP3986458A1 (fr) | 2022-04-27 |
| TW202235428A (zh) | 2022-09-16 |
| TWI828168B (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51311A (fr) | Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
| MA50520A (fr) | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) | |
| MA50524A (fr) | Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb) | |
| MA51292A (fr) | Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb) | |
| PH12019500788A1 (en) | Engineered meganucleases specific for recgonition sequences in the hepatitis b virus genome | |
| EP3668520A4 (fr) | Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations | |
| MA56534A (fr) | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) | |
| MA50335A (fr) | Vaccins à acide nucléique contre des virus respiratoires | |
| PT1685243E (pt) | Linhas celulares aviárias imortalizadas para a produção de vírus | |
| EP4324923A4 (fr) | Inhibiteur d'arn pour inhiber l'expression de gène du virus de l'hépatite b et son application | |
| EA201791343A1 (ru) | Композиции и способы для конструирования вирусного генома in vitro | |
| WO2011015656A3 (fr) | Composition pour le traitement d'une infection par le virus de l'hépatite b | |
| IL288019A (en) | Preparations and methods for treating hepatitis b virus infection | |
| WO2009039248A8 (fr) | Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae | |
| WO2010107739A3 (fr) | Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae | |
| MA51312A (fr) | Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) | |
| EP4022086C0 (fr) | Compositions et procédés pour l'amplification et la détection de l'arn du virus de l'hépatite b, comprenant l'arn du vhb transcrit à partir de adnccc | |
| ZA202305094B (en) | Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus | |
| IL281698A (en) | Monomer and multimeric anti-hbv agents | |
| DK4069729T3 (da) | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet | |
| LT4126932T (lt) | Antikūno molekulės prieš bk virusą | |
| MA56524A (fr) | Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
| IL313397A (en) | Omni-103 CRISPR and RNA nuclease conjugates | |
| HRP20090230T1 (hr) | Replikacijski-defektni rna virusi kao cjepiva | |
| IL290924A (en) | Vaccines for hepatitis b virus |